Back pain can vary from a gentle, unrelenting ache to unbearable pain with the least amount of movement. There are numerous reasons for requesting back pain remedies. The majority of occurrences are associated with soft tissue inflammation surrounding the spinal columm.

Is Back Pain Common?

At least fifteen million men and women search for medical assistance in regards to lower back pain relief each year. Lower back pain relief is runner up to the common cold as a cause of days of work lost and visits to the local pharmacy. Consequently, the market for lower back pain assistance is significant.

What Causes Back Pain?

Back muscular weakness is primarily a result of an inactive routine. This takes account for back pain relates to stress. Back spasms also begins with laborious activities, or if you shift rapidly after staying in an uncomfortable position. Often following a repetitive twisting movement is when a “pulled back” takes place. Lower back pain medications line the shelves of supermarkets and pharmacies, as the necessity for lower back pain relief is widespread. Keep in mind most medications do not heal at the root of the problem like Recovery. Other products are going to be nothing more than a band- aid to your current condition.

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

The intervertebral disks perform as shock absorbers and are exposed to diverse types of pressure and strain throughout the course of daily activities and living. These stresses and tensions outcome may not produce back pain in the moment. In fact, the harm is in fact slowly taking place, the continual trauma start to take its toll. Turning, bending as well as twisting produces compression of the disk, and may cause it to bulge or herniate back towards the nerves and spinal canal. Bending and twisting collectively creates utmost stress on intervertebral disks. Disk degeneration will show its self as chronic or sharp back pain as the muscles preserving the disks go into spasm. The disk degeneration may become inflamed and may possibly cause joint or structural pain.

The lower back known as the lumbar region is the most susceptible to damage. This region receives the more work and use than any other part of the body. This area of the spine tolerates all the burden of the upper body. It bends, twists, flexes and turns on a daily basis. Depending on the amount of strain we put on the lumbar areas will reflect on the amount of wear and tear.

The more wear and tear on the back will ultimately illustrate itself as back pain. This pain is representing damage to the soft tissue which is made up of muscles, ligaments, tendons and the intervertebral disks. The pain is an inflammatory development, a breakdown of the tissue.

Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

Prof Moore, a former Consultant Biochemist at the Radcliffe Infirmary, Oxford, has published many scientific articles. He moved into industry in 1985 as managing director of the UK division of a US diagnostics company, taking it from six to 250 employees and achieving profitability. In 1994, he established his own healthcare consultancy, which has worked for many of the world’s leading pharmaceutical companies, and he has also advised Government.

James Barder, Futura’s chief executive, said: “I am delighted to welcome a scientific adviser of Prof Moore’s calibre to Futura. His huge breadth of experience, particularly in the area of pain relief, will be of great value in the development of TPR100, our pipeline product that uses our topical trans-dermal delivery technology, DermaSys.”

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

For a list of laboratories offering AmpliChip CYP450 Test, go to http://amplichip.us. About Roche and the Roche Diagnostics Division Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche’s Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide.

According to the TGA, Novartis’ Prexige (lumiracoxib) is a Cox 2 inhibitor belonging to the group of medicines known as non-steroidal anti-inflammatory drugs.

Prexige was first approved in Australia in July 2004, but has only recently become widely used since being listed on the Pharmaceutical Benefits Scheme in 2006, the agency added.

As of Aug. 10, According to the Rohan Hammett, TGA’s principal medical adviser, the agency had received eight reports of serious adverse reactions to the drug, including two deaths and two liver transplants.

Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.

Approximately 60,000 Australians take Prexige for symptomatic relief of osteoarthritis, acute pain — including postoperative pain and pain related to dental procedures — and pain due to primary dysmenorrhoea, the agency added.

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

Most of the time, it is the lower back portion of the spine that is usually affected due to normal daily chores such as lifting heavy boxes, improper sitting position, slouching, a sudden awkward movement, or even sleeping on your stomach. Sports injuries from basketball and football, as well as stress on spinal bones and tissues can definitely cause back pain. Other more serious but rare cases of back pain involves spinal injuries such as cancer and infection of the spine. People with recurring back pains or multiple unsuccessful surgeries may develop chronic back pain.

Treatment and Medication
The good news is that back pain is easy to prevent and can be treated even at home. Simple body mechanics can help ease back pain problems within a few weeks. Treatment involves over-the-counter muscle relaxants and anti inflammatory drugs to reduce inflammation and relieve pain. Some tips like constant movement is ideal for healing and quick recovery. Extended bed rest is not advisable as this will aggravate back pain. Using support braces, corsets, back belts should be consulted with your doctors first. There are available braces in the market or your doctor may ask you to have one customized. However, some medical quarters are not in agreement with the idea of using braces. Some very few cases may need surgery and hospitalization unless there is severe pain and serious medical conditions.

Guidance issued by the National Institute for Health and Clinical Excellence (NICE), the watchdog that controls access to drugs on the NHS, will recommend today that the drug does not represent value for money, although it has been shown to improve dramatically the severest symptoms of arthritis in almost half of patients.

The draft ruling comes on the day that Alan Johnson, the Health Secretary, will announce that he is tearing up a price-fixing agreement with pharmaceutical companies in an attempt to reduce unneccessary waste of drug funds.

The Times has learnt that the Health Secretary has decided to take on pharmaceutical giants as the NHS’s £8 billion annual drugs bill comes under pressure from expensive new medicines.
Related Links

* Arthritis drugs offer fresh hope

* Revolutionary drugs usher in new era for patients

* ‘Injection eased pain and made me more energetic’

Abatacept, which has the brand name Orencia, is the latest of a new generation of drugs to be blocked by NICE on the ground that it is not cost-effective.

About 400,000 people in the UK have rheumatoid arthritis, of whom a tenth (40,000) have a severe form. Many benefit from a class of drugs called anti-TNFs but about a third do not. This group, of around 12,000 patients, could potentially benefit from new drugs such as abatacept. Its manufacturer, Bristol Myers Squibb, estimated in its application to NICE that around 3,500 patients a year would benefit.

Published data shows that in trials abatacept produced a 50 per cent reduction in symptoms in about 40 per cent of the patients who used it in conjunction with an older drug, methotrexate.

The cost would be about £9,300 a year for an average patient, but all would be sufferers who had already been treated unsuccessfully with anti-TNF drugs, which are equally expensive. Those who gained no benefit would have been taken off the drug swiftly.

The NICE decision was described by patient groups as devastating. Ailsa Bosworth, chief executive of the National Rheumatoid Arthritis Society (NRAS), said: “This is extremely bad news for people living with severe rheumatoid arthritis.

“Denying patients the option of abatacept leaves some of them with the unacceptable choices of being put back on to treatments they have already failed on, palliative care or taking large doses of steroids, which have unacceptable side-effects over the long term.”

The NICE ruling will be open to consultation, and final guidance is not expected until the end of the year. A spokesman said: “Having examined cost-effectiveness analyses on the drug against a range of comparators, the committee concluded that abatacept could not be considered a costeffective use of NHS resources.”

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

The problems of balancing drug costs against benefits have led a growing number of patients who are denied treatments to resort to legal action.

The Government hopes to free more money for treatments by renegotiating the five-year profit control agreement that it signed with drug companies just two years ago. The move comes after a report by the Office of Fair Trading recommended that the NHS move to a new system that matched the price it pays for drugs to how effective they are, after finding widespread evidence of overcharging.

Some of the most inflated prices are for treatments for blood pressure, cholesterol and stomach acid, which are prescribed to millions of patients a year. Although some cost ten times as much as alternatives they offer little or no extra benefit, the report found. It concluded: “We have identified hundreds of millions of pounds of expenditure per year that could be used more cost-effectively under value-based pricing, allowing patients greater access to drugs and other healthcare benefits they are currently being denied.”

Representatives of pharmaceutical firms were warned by Mr Johnson that he was intending to tear up the agreement. A statement from the Department of Health will seek to strike a conciliatory tone, emphasising the contribution made by drugs giants to the economy and in developing new medicines.

Nevertheless, the drugs industry is likely to fiercely resist attempts to renegotiate the price regulation scheme. In the wake of the competition watchdog’s report this year Richard Barker, the director-general of the Association of the British Pharmaceutical Industry, said: “The UK gets its life- improving and life-saving medicines at a fair and reasonable price.”

A Department of Health official told The Times that Mr Johnson could not ignore the findings of an independent watchdog after a thorough 18-month investigation that compared the prices paid in Britain with those paid abroad. He added that the Health Secretary had not yet decided whether to accept the recommendations in full.

Chronic pain, unlike the acute pain associated with trauma, has no apparent physiological benefit, often being referred to as the ‘disease of pain’.

Complete and lasting relief of chronic pain is rare and often the clinical goal is pain management through one or more medications.

But now researchers at The University of Manchester have examined microscopic amoeboid organisms commonly called slime moulds in a bid to gain greater insight into these pain molecules, known as ‘P2X receptors’.

“In humans, P2X receptors look identical to one another and so scientists have had difficulty understanding how they function,” said Dr Chris Thompson, who carried out the research with Professor Alan North and Dr Sam Fountain in the Faculty of Life Sciences.

“By looking at slime mould we were effectively able to turn the evolutionary clock back a billion years to see how a more primitive P2X molecule functions.”

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

The team discovered that there was only a 10% similarity between human P2X and the slime mould equivalent. They were therefore able to deduce from evolutionary theory that it was these similar parts of the molecule that probably regulate pain in humans.

“It’s a big step forward in understanding how the molecule works and should make it possible to develop drugs that block the receptors’ actions,” said Dr Thompson.

“Inhibiting P2X as a potential pain-relief therapy would be the Holy Grail of rational drug design and could revolutionise the way we manage chronic pain conditions like back pain and migraine.”

The research, published in Nature Thursday, July 12, was funded by the Wellcome Trust, the Medical Research Council and the Lister Institute for Preventive Medicine.

About slime mould

In nature, the slime mould Dictyostelium exists as single-cell amoebae feeding off bacteria in the soil. When their food supply runs out they aggregate to form a ‘fruiting body’ of some 100,000 cells. Some cells become spores, while others form a stalk beneath the soil surface. These stalk cells die; they sacrifice themselves so the spores can be dispersed to new feeding grounds.

Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.

Prexige is considered unique because it is rapidly cleared from the body, it reaches a higher concentration in the joint synovial fluid, and it is preferentially retained in inflamed tissue, allowing for once per day dosing.(4) Prexige is the first COX-2 selective inhibitor to be approved in Canada since the withdrawal of two medications in the same class, in 2004-2005. COX-2s were first marketed in Canada in 1999 as anti-inflammatory medications that caused less gastrointestinal side-effects (e.g. ulcers) than traditional NSAIDs, such as ibuprofen. Following the COX-2 withdrawals, several expert bodies in arthritis held a consensus conference, in 2005, and identified a gap in pain relief for the three million Canadians living with OA. This group, and the arthritis community, concluded that patients need a variety of medications, including COX-2 inhibitors, which are effective and safe. Initially approved for OA of the knee in November, 2006, Prexige has the largest body of evidence supporting the launch of an NSAID, traditional and COX-2, with a clinical trial database of over 34,000 patients. In the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), the largest safety outcomes study published in OA (18,325 patients), Prexige, at four times the recommended OA dose, was compared to the traditional NSAIDs ibuprofen and naproxen.(5,6) TARGET found that Prexige provided a 79 per cent reduction in the incidence of upper GI ulcer complications, among non-aspirin users, in comparison to those treated with traditional NSAIDs naproxen and ibuprofen.(5,6,7) The treatment also showed no significant difference in risk of cardiovascular events, such as heart attack or stroke compared to the other NSAIDs.(6) Recent data presented at the 2007 Annual European Congress of Rheumatology showed that Prexige has significantly less impact on blood pressure than ibuprofen, a commonly-used NSAID.(8) These new results are important because approximately 40 per cent of patients with osteoarthritis also have high blood pressure (or hypertension).(9,10) Novartis is committed to ensuring that Prexige is prescribed appropriately and has launched a comprehensive, long-term study to monitor 20,000 Canadian patients on selected NSAIDs/COX-2 inhibitors, including Prexige. This first-of-its kind, real-life study will further build on the strong body of safety evidence available on Prexige. This commitment will be further supported through strong health education programs for physicians and pharmacists across the country. Forward-looking statement The foregoing release contains forward-looking statements that can be identified by terminology such as “strong,” “sustained pain relief,” “significant” or similar expressions, or by express or implied discussions regarding potential additional marketing approvals or future sales of Prexige. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results with Prexige to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Prexige will receive any additional marketing approvals in any other countries, or that it will reach any particular sales levels. In particular, management’s expectations regarding commercialization of Prexige could be affected by, among other things, additional analysis of Prexige clinical data; new clinical data; unexpected clinical trial results; unexpected regulatory actions or delays or government regulation generally; the company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; increased government, industry, and general public pricing pressures; and other risks and factors referred to in the Company’s current Form 20-F on file with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Canada Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. Novartis Pharmaceuticals Canada conducts hundreds of clinical trials across the country seeking new treatments for cardiovascular disease, diabetes, cancer, organ transplantation, musculoskeletal diseases and ophthalmic diseases. In 2006, the Company invested over $69 million in research and development. Novartis Pharmaceuticals Canada Inc. employs approximately 850 people in Canada and its headquarters are located in Dorval, Quebec. In addition to Novartis Pharmaceuticals Canada Inc., the Novartis Group in Canada consists of Novartis Animal Health Canada Inc.

The recovery was long and it left patients with less ability to move their necks, but there’s a new alternative and a local hospital helped develop it.

The prestige cervical disc is a new implant approved by the Food and Drug Administration.

It’s the first artificial disc for the neck. The implant is two pieces of stainless steel with a ball and groove construction. This allows for some movement.

The spine in the neck consists of seven bones. In between the bones is a spongy, cushiony disc which allows for rotation and bending.

Traditionally, surgical treatment involves removing a diseased disc and fusing two or more of the bones.

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

With the new implant, the doctors take out the discs that aren’t working right. They attach the artificial disc into the neighboring neck bones.

“For the first time we have a motion-preserving device that lets you keep motion in your spine,” Dr. Donald Whiting, from Allegheny General Hospital, said.

FDA approval is based on research in more than 500 people which showed this procedure is just as safe and effective as the traditional approach.

“What we don’t know yet is will it reduce the wear and tear on the levels above and below,” Whiting said. “Ten years down the road, 20 years down the road, we don’t know, we may have to go back in and correct it.”

Right now, insurance may not cover it and further study over the next seven years will look at longer term safety and effectiveness.

(LOGO: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

“We believe that the results of our Phase IIb trial support the validity of our POSIDUR product concept of simultaneously relieving pain while reducing opioid consumption,” stated James Brown, President and CEO of DURECT Corporation. “Our partnership with Nycomed provides us with financial and development support along with a strong marketing presence to commercialize POSIDUR in Europe and other countries. We intend to market POSIDUR ourselves in the U.S., if approved, thus providing us with a pathway to establishing our own specialty pharmaceutical business.”

Phase IIb Inguinal Hernia Trial

Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.

Design

The POSIDUR Phase IIb clinical trial was designed to evaluate the tolerability, activity, dose response and pharmacokinetics of POSIDUR in patients undergoing open inguinal hernia repair. The study was conducted in Australia and New Zealand as a multi-center, randomized, double blind, placebo-controlled study in 122 patients. Study patients were randomized into three treatment groups: patients that were treated with POSIDUR 2.5 mL (n=43), POSIDUR 5 mL (n=47) and placebo (n=32). The co-primary efficacy endpoints for the study were Mean Pain Intensity on Movement area under the curve (AUC), a measure of pain over a period of time, 1-72 hours post-surgery, and the proportion of patients requiring supplemental opioid analgesic medication during the study. Secondary efficacy endpoints included Mean Pain Intensity on Movement AUC over the period 1-48 hours post-surgery, mean total consumption of supplemental opioid analgesic medication, and time to first use of supplemental opioid analgesic medication. The threshold for statistical significance was considered to be at the p<0.05 level.

Results

Pain Control

In relation to the co-primary endpoint of pain reduction as measured by Mean Pain Intensity on Movement AUC 1-72 hours post-surgery, the patient group treated with POSIDUR 5 mL reported thirty-one percent (31%) less pain versus placebo (p=0.0033). A thirty-five percent (35%) reduction of pain as measured by Mean Pain Intensity on Movement AUC for the period 1-48 hours post-surgery, a secondary endpoint measure, was reported between the POSIDUR 5 mL treatment group versus placebo (p=0.0007).